CagriSema vs MOTS-c
A side-by-side research comparison of CagriSema and MOTS-c across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CagriSema | MOTS-c |
|---|---|---|
| Full name | CagriSema (Cagrilintide + Semaglutide) | Mitochondrial Open Reading Frame of the 12S rRNA-c |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Research compound |
| Mechanism | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. | Activates AMPK pathway, enhances mitochondrial metabolism, improves insulin sensitivity by increasing GLUT4 translocation, and promotes fatty acid oxidation. |
| Molecular weight | Combination product | 2,175 Da |
| Half-life | 7 days (both components) | 4-8 hours |
| Bioavailability | High (SubQ) | Moderate (SubQ) |
| Typical dose | Cagrilintide 2.4mg + Semaglutide 2.4mg | 5-10 mg |
| Frequency | Once weekly | 3-5x per week |
| Route | Subcutaneous | Subcutaneous injection |
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
MOTS-c reported benefits
- Exercise mimetic effects
- Improved insulin sensitivity
- Enhanced fat oxidation
- Metabolic homeostasis
- Anti-aging metabolic benefits
- AMPK activation
Related comparisons
Research and educational reference only. Not medical advice.